Muscle Cell News 3.38 November 19, 2018 | |
| |
TOP STORYNotch-Induced miR-708 Antagonizes Satellite Cell Migration and Maintains Quiescence Researchers employed in vivo and ex vivo functional studies, in addition to live imaging, to show that miR-708 regulated quiescence and self-renewal by antagonizing cell migration through targeting the transcripts of the focal-adhesion-associated protein Tensin3. [Cell Stem Cell] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)CARDIAC MUSCLE CELLSUse of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Assess Drug Cardiotoxicity The authors describe how to differentiate human induced pluripotent stem cells (hiPSCs) into hiPSC-cardiomyocytes (CMs) and subsequently implement contractility and cytotoxicity assays that can evaluate drug-induced cardiotoxicity in hiPSC-CMs. [Nat Protoc] Abstract Hypoxic stress induced the interaction of filamin A with the GTPase domain of dynamin-related protein 1 (Drp1) and increased Drp1 activity in an actin-binding-dependent manner in rat cardiomyocytes. Expression of the A1545T filamin mutant, which potentiates actin aggregation, promoted mitochondrial hyperfission under normoxia. [Sci Signal] Full Article | Press Release Atrial-Like Engineered Heart Tissue: An In Vitro Model of the Human Atrium Scientists used recent retinoic acid-based protocols to generate atrial cardiomyocytes from human induced pluripotent stem cells and established right atrial engineered heart tissue as a 3D model of human atrium. [Stem Cell Reports] Full Article | Editorial | Graphical Abstract Doxorubicin-Induced Cardiotoxicity Involves IFNγ-Mediated Metabolic Reprogramming in Cardiomyocytes In vitro, Interferon-γ (IFNγ) strongly aggravated the injury of cardiomyocytes exposed to doxorubicin (DOX). Although not affecting DOX-induced cell death, IFNγ disrupted mitochondrial respiration and fatty acid oxidation in DOX-exposed cardiomyocytes. IFNγ extended the suppression of the AMP-activated protein kinase/acetyl-CoA carboxylase axis by DOX to a p38-dependent branch. [J Pathol] Abstract SKELETAL MUSCLE CELLSThe Ubiquitin-Proteasome System Is Indispensable for the Maintenance of Muscle Stem Cells Researchers investigated the function of the proteasome in satellite cells using mice lacking the crucial proteasomal component, Rpt3. They found that inactivation of proteasomal activity induced proliferation defects and apoptosis in satellite cells. Mechanistically, insufficient proteasomal activity upregulated the p53 pathway, which caused cell-cycle arrest. [Stem Cell Reports] Full Article | Graphical Abstract During the proliferation phase, the overexpression of miR-483 downregulated cell cycle–associated genes cyclin-dependent kinase 2, proliferating cell nuclear antigen mRNA, and protein levels. At the cellular level, cell cycle, cell counting kit-8, and 5-ethynyl-2´-deoxyuridine results indicated that the overexpression of miR-483 blocked cell proliferation. [J Cell Physiol] Abstract The authors showed that, overexpression of circular RNA fibroblast growth factor receptor 2 (circFGFR2) accelerated the proliferation of myoblast and QM-7 cells, whereas knockdown of circFGFR2 with siRNA reduced the proliferation of both cells. [Cells] Full Article SMOOTH MUSCLE CELLSFunctional Regulatory Mechanism of Smooth Muscle Cell-Restricted LMOD1 Coronary Artery Disease Locus Leiomodin 1 (LMOD1) knockdown resulted in increased proliferation and migration and decreased cell contraction in human coronary artery smooth muscle cells (SMCs), and immunostaining in atherosclerotic lesions in the SMC lineage tracing reporter mouse support a key role for LMOD1 in maintaining the differentiated SMC phenotype. [PLoS Genet] Full Article Mechanistically, PDGF-BB induced prolonged Akt activation that caused decreased autophagosome biogenesis and thereby exaggerated p62/SQSTM1 accumulation in Smpd1−/− smooth muscle cells (SMCs). More importantly, Akt inhibition or p62/SQSTM1 gene silencing attenuated PDGF-BB-induced phenotypic changes in Smpd1−/− SMCs. [Cell Death Dis] Full Article The effect of 2,4,6-trihydroxy-3-geranyl acetophenone (tHGA) upon human airway smooth muscle proliferation, migration and survival in response to growth factors was assessed and its molecular target was determined. [Sci Rep] Full Article A Rapamycin Derivative, Biolimus, Preferentially Activates Autophagy in Vascular Smooth Muscle Cells Investigators showed that two major rapalogues, everolimus and biolimus, exerted a differential effect on the mTORC1-mediated signaling pathways in vascular smooth muscle cells. [Sci Rep] Full Article Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & ESC & iPSC News. | |
| |
REVIEWSTargeting Epigenetics and Non-Coding RNAs in Atherosclerosis: From Mechanisms to Therapeutics The authors provide a systematic and up-to-date overview of the current knowledge of three distinct but interrelated epigenetic processes, in atherosclerotic plaque development and instability. Mechanistic and conceptual advances in understanding the biological roles of various epigenetic modifiers in regulating gene expression and functions of endothelial cells, smooth muscle cells, and macrophages are discussed. [Pharmacol Ther] Abstract Diagnosis and Treatment of Mitochondrial Myopathies The diagnosis of mitochondrial myopathy is reliant on the combination of numerous techniques including traditional histochemical, immunohistochemical, and biochemical testing combined with the fast-emerging molecular genetic techniques, namely next-generation sequencing. [Neurotherapeutics] Full Article Visit our reviews page to see a complete list of reviews in the muscle cell research field. | |
| |
SCIENCE NEWSCardurion Pharmaceuticals Presents Preclinical Data for CRD-733 Cardurion Pharmaceuticals announced preclinical results from its study of CRD-733, the company’s novel phosphodiesterase-9 enzyme inhibitor, in a poster presentation. [Press release from Cardurion Pharmaceuticals discussing research presented at the American Heart Association (AHA) Scientific Sessions, Chicago] Press Release MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance MyoKardia, Inc. presented preclinical data that demonstrated that targeting the heart’s motor protein, myosin, improved ventricular relaxation and compliance and normalized systolic function. [Press release from MyoKardia, Inc. discussing research presented at the American Heart Association (AHA) Scientific Sessions, Chicago] Press Release | |
| |
INDUSTRY NEWSThe one-year collaboration between Catabasis and Dr. Pradeep Mammen will utilize the muscular dystrophy mdx mouse model with reduced utrophin as these animals display an early and prominent cardiomyopathy. [Catabasis Pharmaceuticals, Inc.] Press Release Myonexus Therapeutics in collaboration with Nationwide Children’s Hospital’s Center for Gene Therapy and Sarepta Therapeutics, announced the initiation of a clinical trial evaluating MYO-101, a novel gene therapy candidate for beta-sarcoglycanopathy, also known as Limb-Girdle Muscular Dystrophy Type 2E. [Myonexus Therapeutics] Press Release NeuroVive Pharmaceutical AB announced that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova, Sweden’s innovation agency, and the Swelife call, for intensified development in the NVP015 project, the goal of which is to advance the candidate compound NV354 to clinical studies. [NeuroVive Pharmaceutical AB (PR Newswire Association LLC.)] Press Release Evox Therapeutics Wins Funding from Duchenne UK to Explore Exosome-Mediated Delivery of Dystrophin Evox Therapeutics Ltd announced that it has secured £655,000 in funding from Duchenne UK. The grant will be invested to support exploration of the company’s exosome-based therapeutic platform to deliver either full-length dystrophin or its shorter variants in pre-clinical models of Duchenne muscular dystrophy. [Evox Therapeutics Ltd] Press Release Mukesh K Jain, MD, and his colleagues have been awarded a five-year, $6M grant from the Paris-based Fondation Leducq to conduct a thorough analysis of the pivotal role of kruppel-like factor 2 in vascular-related functions and disorders. [Case Western Reserve University] Press Release Capricor to Meet with FDA under Its RMAT Designation to Discuss HOPE-2 Clinical Trial Capricor Therapeutics announced that it will meet with the FDA in December to discuss clinical trial design, surrogate or intermediate endpoints and manufacturing processes for CAP-1002, Capricor’s novel cell therapy. Currently, patients are being enrolled in the HOPE-2 clinical trial, which is investigating CAP-1002 as a therapy for the treatment of Duchenne muscular dystrophy. [Capricor Therapeutics] Press Release Metcalf Prizes for Stem Cell Research: 2018 Winners Announced Winners of the National Stem Cell Foundation of Australia’s 2018 Metcalf Prizes announced. Associate Professor Enzo Porrello is exploring newborn heart development to develop heart attack drugs and engineer ‘artificial pumps’ from patient stem cells. [National Stem Cell Foundation of Australia] Press Release | |
| |
POLICY NEWSCan Novartis Charge $4 Million for a One-Time Drug? Novartis believes its new gene therapy is worth more than $4 million for a one-time dose, and the company has some data to back that up. The treatment, called AVXS-101, has demonstrated dramatic effects in spinal muscular atrophy, a rare genetic disorder whose most severe form is fatal for almost all patients before age 2. [STAT News] Editorial Duke University to Settle Case Alleging Researchers Used Fraudulent Data to Win Millions in Grants Duke University in Durham, North Carolina, is on the verge of settling a case brought by a former employee who claims the university included faked data in applications and reports for federal grants worth nearly $200 million. [ScienceInsider] Editorial French Science Behemoth Launches Research-Integrity Office France’s national research center, the CNRS, has announced plans to create its first office of research integrity to investigate scientific misconduct and promote good research practice. [Nature News] Editorial
| |
EVENTSNEW Cardiology World Conference: Advances in Cardiology: Research and Innovations Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Assistant/Associate Adjunct Professor – Cardiovascular Medicine (UC Davis) NEW Postdoctoral Research Fellow – Cardiac RNA Biology (University of Illinois at Chicago) Postdoctoral Position – Cardiac Hypertrophy & Heart Failure (Masonic Medical Research Laboratory) Postdoctoral Fellow – Muscle Degeneration (Rice University) Assistant/Associate Professor – Exercise Science (Syracuse University) Postdoctoral Position – Cardiomyocyte Mechanobiology (Queen Mary University of London) Postdoctoral Research Scientist – Integrative Cardiac Pathophysiology (Columbia University) Postdoctoral Associate Specialist – Muscle Aging Biology (Nestle Research – EPFL Campus) Faculty Position – Cardiovascular Diseases (Mayo Clinic) Postdoctoral Fellow – Cardiovascular Tissue Engineering (Stanford University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Muscle Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|